Study Design and Patient Demographics of the ULTIMATE Phase III Trials Evaluating Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Multiple Sclerosis (RMS)

Drug Category : Array
Conference Category : Array
Lead Author : Cree B, et al.
Published Date : 12/09/2019
Download Link : https://www.tgtherapeutics.com/FINAL%20TGTX%20ECTRIMS%202019%20ULTIMATE.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top